SCHEMBL2373944

SCHEMBL2373944

Cc1ccc(C)c(C(=O)O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 3/20 0.39
OPRK1 P41145 1/20 0.39
MAPK1 P28482 1/20 0.39
PIN1 Q13526 1/20 0.39
GRM5 P41594 2/20 0.39
RAB9A P51151 2/20 0.37
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
SORT1 Q99523 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 2/20 0.36
AKR1C3 P42330 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6110055 0.82 KMT2A (0.39) ALDH1A1SMN1; SMN2MAPTKMT2AOPRK1
SCHEMBL2222443 0.80 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2MAPTMAPK1PIN1
SCHEMBL19857471 0.80 KDM4E (0.48) ALDH1A1SMN1; SMN2MAPTKMT2AMAPK1
SCHEMBL29625359 0.80 GABRP (0.47) ALDH1A1SMN1; SMN2MAPTKMT2ASORT1
SCHEMBL29771502 0.80 PARP1 (0.46) KMT2AOPRK1GRM5RAB9ACCR1
SCHEMBL262422 0.80 GABRP (0.47) ALDH1A1SMN1; SMN2MAPTKMT2ASORT1
SCHEMBL18806275 0.80 KMT2A (0.38) ALDH1A1SMN1; SMN2MAPTKMT2AOPRK1
SCHEMBL18837073 0.80 PARP1 (0.46) KMT2AOPRK1GRM5RAB9ACCR1
SCHEMBL1759159 0.80 GRM5 (0.53) ALDH1A1SMN1; SMN2MAPTKMT2AOPRK1
SCHEMBL847125 0.78 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MAPTMAPK1PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102791714-B N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors HOFFMANN LA ROCHE 2015-03-25 CN claimed
EP-2552918-B1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS HOFFMANN LA ROCHE (CH) 2014-06-11 EP claimed
US-8410117-B2 Imidazopyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-02 US claimed
EP-2552918-A1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS F. Hoffmann-La Roche AG (CH) 2013-02-06 EP claimed
CN-102791714-A N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as PDE10A inhibitors HOFFMANN LA ROCHE 2012-11-21 CN claimed
CN-113195053-B Amino acid compounds and methods of use 普利安特治疗公司 2024-08-30 CN disclosed
US-20230151002-A1 6-5 FUSED RINGS AS C5a INHIBITORS CHEMOCENTRYX, INC. 2023-05-18 US disclosed
US-20230151002-A1 6-5 FUSED RINGS AS C5a INHIBITORS CHEMOCENTRYX, INC. 2023-05-18 US disclosed
CN-111065383-A Carboxamides useful as sodium channel modulators 沃泰克斯药物股份有限公司 2020-04-24 CN disclosed
CN-110177786-A Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor 阿雷生物药品公司 2019-08-27 CN disclosed
US-20180057505-A1 BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY VERTEX PHARMACEUTICALS INCORPORATED 2018-03-01 US disclosed
US-9668482-B1 Fused heterocyclic compound and pest control application thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-06-06 US disclosed
WO-2002062787-A1 PYRAZOLES AS TGF INHIBITORS GLAXO GROUP LIMITED (GB) 2002-08-15 WO disclosed
US-5741802-A FOR TREATMENT OF MEMORY LOSS UNIVERSITY OF FLORIDA (US) 1998-04-21 US disclosed
EP-0659078-A4 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM. UNIV FLORIDA (US) 1996-04-24 EP disclosed
EP-0659078-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 1995-06-28 EP disclosed
WO-1994005288-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM UNIVERSITY OF FLORIDA (US) 1994-03-17 WO disclosed
EP-0053789-B1 2-PYRIDINECARBOXAMIDE DERIVATIVE, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION, USEFUL AS AN ANTI-ALLERGIC AGENT Tanabe Seiyaku Co., Ltd. (JP) 1985-03-27 EP disclosed
US-4404214-A 2-Pyridinecarboxamide derivatives compositions containing same and method of using same TANABE SEIYAKU CO., LTD. (JP) 1983-09-13 US disclosed
EP-0053789-A1 2-Pyridinecarboxamide derivative, process for preparing same and pharmaceutical composition, useful as an anti-allergic agent Tanabe Seiyaku Co., Ltd. (JP) 1982-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151002-A1 6-5 FUSED RINGS AS C5a INHIBITORS C5AR1, C5AR2, C3AR1 ALDH1A1 3166/4885SMN1; SMN2 3141/4885MAPT 4546/4885
US-20180057505-A1 BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY F2RL1, PARP12, TFPI2 ALDH1A1 3037/4885SMN1; SMN2 4014/4885MAPT 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.